

PATENT

Attorney Docket No. NUCI-006/01US

Application No. 10/560,377

(US Nat'l. Stage of PCT/US04/19229

Page 1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Catherine J. PACHUK *et al.* Confirmation No.: 3823

Application No.: 10/560,377

Group Art Unit: *To Be Assigned*

Int'l. Filing Date: June 10, 2004

Examiner: *To Be Assigned*

For: **Conserved HBV and HCV Sequences Useful for Gene Silencing**

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,

Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, copies of documents 2-13 cited in the attached Form PTO-1449 are enclosed.
- ☐ Copies of the remaining publications listed on the attached Form PTO-1449 are not being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial Nos.:
to which the above-identified application claims priority under 35 U.S.C. §120.
- ☐ Copies of documents that were not submitted in the above-mentioned related United States Patent Applications may be found in related United States Patent Application Nos.:
Should the Examiner be unable to locate a document, a copy will be provided upon request.
- ☒ No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO-1449 are being provided pursuant to 37 C.F.R. §1.98.

- [x] Document 2 is the PCT Patent publications of Applicants' related PCT Application no. PCT/US04/19229, filed June 10, 2004.
- [x] Documents 1 and 5-13 were cited in a Search Report mailed October 12, 2006 (cited herein as document 4), in Applicants' related SG Application no. 200507781-3.
- [x] Documents 3 and 4 are official communications from foreign patent offices received in Applicants' related SG Application no. 200507781-3.
- [] Documents _____ submitted herewith were not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.
- [] Enclosed is a copy of a non-English publication(s) _____. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- [] Enclosed is a copy of a non-English publication(s) _____. English language publication _____ (copy enclosed) claims priority from this non-English publication.
- [] Enclosed are abstracts of non-English publications _____, cited herein as documents _____ respectively. English abstracts are attached to each document. An English abstract of non-English publication _____, document _____, may be found on the cover page of the publication.
- [] Enclosed is an English translation of non-English publications _____, cited herein as documents _____ respectively. English translations are attached to each document.
- [] The Examiner's attention is directed to related co-pending United States Patent Application Serial Nos.: _____, filed _____, cited herewith as _____; and

_____, filed _____, cited herewith as _____.

This Information Disclosure Statement is filed within any one of the following time periods:

- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in this international application;
- ☒ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Forms PTO-1449 to the undersigned. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-1283.

Dated: Dec. 26, 2006

USPTO Customer No. 58249
COOLEY GODWARD KRONISH LLP
ATTN: Patent Group
The Bowen Building
875 15th Street, NW Suite 800
Washington, DC 20005-2221
Phone: (202) 842-7800
Fax: (202) 842-7899

Respectfully submitted,
COOLEY GODWARD KRONISH LLP

By:

Bonnie Weiss McLeod
Bonnie Weiss McLeod
Reg. No. 43,255

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449		Attorney Docket No. NUCL-006/01US	Application No. 10/560,377 (US Nat'l. Stage of PCT/US04/19229)	
Applicants: Catherine J. PACHUK <i>et al.</i>		PAGE 1 of 1		
Int'l. Filing Date: June 10, 2004		Group Art Unit: <i>To Be Assigned</i>		

U.S. PATENT DOCUMENTS						
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
/B.P./	1.	6,518,417	02/11/2003	Sczakiel <i>et al.</i>		

FOREIGN PATENT DOCUMENTS						
Document No.	Date	Country	Class	Sub-Class	Translation	
/B.P./	2.	WO 2005/014806	02/17/2005	WIPO		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
/B.P./	3. Mackenzie, "Written Opinion," from SG 200507781-3, filed June 10, 2004, 6 pages, Australian Patent Office (mailed October 12, 2006).
4.	Mackenzie, "Search Report," from SG 200507781-3, filed June 10, 2004, 7 pages, Australian Patent Office (mailed October 12, 2006).
5.	Andino, "RNAi puts a lid on virus replication," <i>Nat. Biotechnol.</i> 21 (6):629-630 (2003).
6.	Couzin, "Mini RNA Molecules Shield Mouse Liver From Hepatitis," <i>Science</i> 299 :995 (2003).
7.	Hamasaki <i>et al.</i> , "Short interfering RNA-directed inhibition of hepatitis B virus replication," <i>FEBS Letters</i> 543 :51-54 (2003).
8.	Kapadia <i>et al.</i> , "Interference of hepatitis C virus RNA replication by short interfering RNAs," <i>Proc. Natl. Acad. Sci. USA</i> 100 (4):2014-2018 (2003).
9.	McCaffrey <i>et al.</i> , "RNA interference in adult mice," <i>Nature</i> 418 :38-39 (2002).
10.	McCaffrey <i>et al.</i> , "Inhibition of hepatitis B virus in mice by RNA interference," <i>Nat. Biotechnol.</i> 21 (6):639-644 (2003).
11.	Seo <i>et al.</i> , "Small Interfering RNA-Mediated Inhibition of Hepatitis C Virus Replication in the Human Hepatoma Cell Line Huh-7," <i>J. Virol.</i> 77 (1):810-812 (2003).
12.	Shlomai and Shaul, "Inhibition of Hepatitis B Virus Expression and Replication by RNA Interference," <i>Hepatology</i> 37 :764-770 (2003).
13.	Wilson <i>et al.</i> , "RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells," <i>Proc. Natl. Acad. Sci. USA</i> 100 (5):2783-2788 (2003).

Examiner: /Bo Peng/	Date Considered: 06/18/2009
---------------------	-----------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.